Daliresp: Advanced COPD Management for Improved Respiratory Function
Daliresp
| Product dosage: 500 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | 2.65 $ | 79.56 $ (0%) | 🛒 Add to cart |
| 60 | 2.15 $ | 159.12 $ 128.70 $ (19%) | 🛒 Add to cart |
| 90 | 1.85 $ | 238.68 $ 166.14 $ (30%) | 🛒 Add to cart |
| 120 | 1.61 $ | 318.24 $ 193.05 $ (39%) | 🛒 Add to cart |
| 180 | 1.43 $
Best per tab | 477.36 $ 257.40 $ (46%) | 🛒 Add to cart |
Daliresp (roflumilast) is a prescription medication specifically designed for the treatment of severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis and a history of exacerbations. It belongs to a class of drugs known as phosphodiesterase 4 (PDE4) inhibitors, which work by reducing inflammation in the lungs, thereby decreasing the frequency of flare-ups or worsening of COPD symptoms. This oral tablet is intended for use as a maintenance treatment in adults and should be part of a comprehensive management plan that may include bronchodilators. By targeting the underlying inflammatory processes, Daliresp helps patients achieve better disease control and an enhanced quality of life.
Features
- Active ingredient: Roflumilast
- Dosage form: Oral tablet
- Available strengths: 500 mcg
- Prescription-only medication
- PDE4 inhibitor class
- Once-daily dosing regimen
Benefits
- Reduces the risk of COPD exacerbations in susceptible patients
- Decreases inflammation in the airways, improving overall lung function
- Helps maintain respiratory stability over the long term
- Complements existing COPD therapies for a multifaceted treatment approach
- Supports enhanced daily activity tolerance and quality of life
- Contributes to fewer hospitalizations and emergency visits due to severe flare-ups
Common use
Daliresp is indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. It is not a bronchodilator and is not indicated for the relief of acute bronchospasm. It is typically prescribed for adults as part of a comprehensive COPD management program, which may include smoking cessation, pulmonary rehabilitation, and other medications.
Dosage and direction
The recommended dosage of Daliresp is one 500 mcg tablet taken orally once daily, with or without food. It is important to take Daliresp at the same time each day to maintain consistent blood levels. The tablet should be swallowed whole and not crushed, chewed, or broken. Dosage adjustments are not typically required for elderly patients or those with renal impairment, but caution is advised in patients with moderate to severe liver impairment. Treatment should be initiated under the supervision of a healthcare provider experienced in managing COPD.
Precautions
Patients should be monitored for weight loss during treatment, as Daliresp has been associated with progressive, unintentional weight decrease. Mental health changes, including insomnia, anxiety, and depression, should be watched for and reported promptly. Use with caution in patients with a history of depression or suicidal thoughts. Liver function tests are recommended prior to initiation and periodically during treatment. Daliresp is not a substitute for corticosteroids or bronchodilators and should not be used to treat acute symptoms.
Contraindications
Daliresp is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). It is also contraindicated in patients with a known hypersensitivity to roflumilast or any component of the formulation. Due to the potential for psychiatric adverse effects, caution is advised, but there are no absolute contraindications based solely on psychiatric history unless outweighing benefits.
Possible side effect
Common side effects may include diarrhea, weight loss, nausea, headache, insomnia, back pain, decreased appetite, and dizziness. Less frequently, psychiatric events such as anxiety, depression, and suicidal ideation have been reported. Some patients may experience gastrointestinal disturbances or infections. Most side effects are mild to moderate and often decrease over time, but any persistent or severe symptoms should be discussed with a healthcare provider.
Drug interaction
Daliresp may interact with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin), which can decrease roflumilast exposure and reduce efficacy. Concurrent use with immunosuppressants or other anti-inflammatory agents should be monitored. Although no significant interactions have been noted with common bronchodilators, always inform your healthcare provider of all medications, including over-the-counter drugs and supplements.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is near the time of the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Consistency in dosing is important to maintain therapeutic levels, so efforts should be made to adhere to the prescribed regimen.
Overdose
In case of suspected overdose, symptomatic and supportive care is recommended. There is no specific antidote for roflumilast overdose. Symptoms may include gastrointestinal distress, headache, lightheadedness, and possibly intensified adverse effects. Patients should seek immediate medical attention or contact a poison control center. Management may include monitoring vital signs and providing symptomatic relief.
Storage
Store Daliresp at room temperature, between 20°C to 25°C (68°F to 77°F), in a dry place away from light and moisture. Keep the medication in its original container, tightly closed, and out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local guidelines or through a medicine take-back program.
Disclaimer
This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual patient needs and responses may vary, and only a healthcare professional can determine the appropriate therapy based on specific health conditions and overall medical history.
Reviews
Clinical studies and patient reports indicate that Daliresp can be effective in reducing exacerbations in appropriate COPD patients. Many users report a noticeable decrease in the frequency of severe flare-ups over time, contributing to improved daily functioning. However, side effects such as weight loss and gastrointestinal issues are commonly noted, and adherence may be challenging for some. Overall, it is considered a valuable option in severe COPD management when used under medical supervision. Long-term benefits often outweigh initial side effects for committed patients.